92 related articles for article (PubMed ID: 25036475)
21. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
[TBL] [Abstract][Full Text] [Related]
22. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
23. Position paper of Italian rheumatologists on the use of biosimilar drugs.
Atzeni F; Sebastiani M; Ricci C; Celano A; Gremese E; Iannone F; Meroni PL; Minghetti P; Sarzi-Puttini P; Ferraccioli G; Lapadula G
Clin Exp Rheumatol; 2015; 33(1):1-4. PubMed ID: 25436597
[TBL] [Abstract][Full Text] [Related]
24. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe.
Tsiftsoglou AS; Trouvin JH; Calvo G; Ruiz S
BioDrugs; 2014 Dec; 28(6):479-86. PubMed ID: 25391420
[TBL] [Abstract][Full Text] [Related]
25. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
26. Preface: issues in biosimilar drug development.
Yao B; Chi E
J Biopharm Stat; 2014; 24(6):1137. PubMed ID: 25360866
[No Abstract] [Full Text] [Related]
27. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
[TBL] [Abstract][Full Text] [Related]
28. Use of genetic technologies to compare medicines.
Kolitz SE; Towfic F; Grossman I; Hayden MR; Zeskind B
Clin Genet; 2014 Nov; 86(5):441-6. PubMed ID: 25046029
[TBL] [Abstract][Full Text] [Related]
29. BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints.
Chi X; Yu Z; Lin R
Stat Med; 2022 Nov; 41(26):5319-5334. PubMed ID: 36127794
[TBL] [Abstract][Full Text] [Related]
30. Biosimilars: policy, clinical, and regulatory considerations.
Gottlieb S
Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
[TBL] [Abstract][Full Text] [Related]
31. Biosimilars: where we were and where we are.
Challand R; Gorham H; Constant J
J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
[TBL] [Abstract][Full Text] [Related]
32. [Regulatory aspects of biosimilars. Myths and facts].
Schneider CK; Weise M
Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
[TBL] [Abstract][Full Text] [Related]
33. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
Carver KH; Elikan J; Lietzan E
Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
[TBL] [Abstract][Full Text] [Related]
34. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
Dranitsaris G; Amir E; Dorward K
Drugs; 2011 Aug; 71(12):1527-36. PubMed ID: 21861538
[TBL] [Abstract][Full Text] [Related]
35. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
Endrenyi L; Markus R
J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
